Jeffrey M. Dayno - Aug 26, 2021 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
Chief Medical Officer
Signature
/s/ Christian Ulrich, Attorney-in-fact
Stock symbol
HRMY
Transactions as of
Aug 26, 2021
Transactions value $
-$269,082
Form type
4
Date filed
8/30/2021, 04:31 PM
Previous filing
Aug 11, 2021
Next filing
Sep 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $17.7K +2.16K $8.22* 2.16K Aug 26, 2021 Direct
transaction HRMY Common Stock Sale -$75.6K -2.16K -100% $35.01 0 Aug 26, 2021 Direct F1, F2
transaction HRMY Common Stock Options Exercise $64.5K +7.84K $8.22* 7.84K Aug 27, 2021 Direct
transaction HRMY Common Stock Sale -$276K -7.84K -100% $35.16 0 Aug 27, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -2.16K -2.31% $0.00 91.3K Aug 26, 2021 Common Stock 2.16K $8.22 Direct F4
transaction HRMY Stock Option Options Exercise $0 -7.84K -8.59% $0.00 83.5K Aug 27, 2021 Common Stock 7.84K $8.22 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.09. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.43. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021.